Evaluation of Maternal Serum Fibroblast Growth Factor-23 Levels in Fetal Growth Restriction and Gestational Hypertensive Disease

Overview

Journal Rev Assoc Med Bras (1992)

Specialty General Medicine

Date 2024 Jul 24

PMID 39045952

Authors

Erdener Karacan

Umran Kilincdemir Turgut

Halil Ibrahim Buyukbayram

Mehmet Guney

Affiliations

Soon will be listed here.

Abstract

Objective: The objective of this study was to determine serum fibroblast growth factor-23 levels in preeclampsia, eclampsia, gestational hypertension, and the presence of fetal growth restriction subgroups.

Methods: A total of 55 pregnant women with planned cesarean section were included in this cross-sectional study. They were divided into two groups, namely, control (25) and gestational hypertensive disease (30). The gestational hypertensive disease group was evaluated by dividing it into three subgroups (preeclampsia, eclampsia, and gestational hypertension) according to the clinical and laboratory findings of the disease and two subgroups (presence of fetal growth restriction and absence of fetal growth restriction) according to the birth weight percentile. Demographic parameters, obstetric history, physical examination findings, and laboratory values were evaluated.

Results: Demographic parameters and obstetric history were similar between the two groups, while gestational week of delivery was lower in the gestational hypertensive disease group (p=0.002). Laboratory parameters and serum fibroblast growth factor-23 (pg/mL) values were similar between the two groups. In the subgroup analysis for gestational hypertension, preeclampsia, and eclampsia, there was no statistically significant difference in serum fibroblast growth factor-23 levels between gestational hypertension, preeclampsia, eclampsia, and control groups. In the subgroup analysis based on the presence of fetal growth restriction, serum fibroblast growth factor-23 levels were similar to the control group in the gestational hypertensive disease absence of fetal growth restriction, while serum fibroblast growth factor-23 levels and serum calcium levels were statistically significantly lower in the gestational hypertensive disease with the presence of fetal growth restriction (p=0.044 and p<0.001, respectively).

Conclusion: Serum fibroblast growth factor-23 levels are similar between pregnancies complicated with gestational hypertensive disease and normotensive pregnancies. However, serum fibroblast growth factor-23 levels were found to be lower in pregnancies complicated with gestational hypertensive disease with the presence of fetal growth restriction.

References

Qamar H, Perumal N, Papp E, Gernand A, Al Mahmud A, Roth D . Higher maternal parathyroid hormone concentration at delivery is not associated with smaller newborn size. Endocr Connect. 2021; 10(3):345-357. PMC: 8052570. DOI: 10.1530/EC-21-0056. View

Malas N, Shurideh Z . Does serum calcium in pre-eclampsia and normal pregnancy differ?. Saudi Med J. 2001; 22(10):868-71. View

Kizilgul M, Kan S, Beysel S, Apaydin M, Ozcelik O, Caliskan M . Is fibroblast growth factor 23 a new cardiovascular risk marker in gestational diabetes?. Arch Endocrinol Metab. 2017; 61(6):562-566. PMC: 10522065. DOI: 10.1590/2359-3997000000287. View

Itoh N, Ornitz D . Functional evolutionary history of the mouse Fgf gene family. Dev Dyn. 2007; 237(1):18-27. DOI: 10.1002/dvdy.21388. View

Macdonald-Wallis C, Lawlor D, Fraser A, May M, Nelson S, Tilling K . Blood pressure change in normotensive, gestational hypertensive, preeclamptic, and essential hypertensive pregnancies. Hypertension. 2012; 59(6):1241-8. PMC: 3378662. DOI: 10.1161/HYPERTENSIONAHA.111.187039. View

Miranda J, Romero R, Korzeniewski S, Schwartz A, Chaemsaithong P, Stampalija T . The anti-aging factor α-klotho during human pregnancy and its expression in pregnancies complicated by small-for-gestational-age neonates and/or preeclampsia. J Matern Fetal Neonatal Med. 2013; 27(5):449-57. PMC: 4157896. DOI: 10.3109/14767058.2013.818652. View

Cecati M, Giannubilo S, Saccucci F, Sartini D, Ciavattini A, Emanuelli M . Potential Role of Placental Klotho in the Pathogenesis of Preeclampsia. Cell Biochem Biophys. 2016; 74(1):49-57. DOI: 10.1007/s12013-015-0710-9. View

Quarles L . Fibroblast growth factor 23 and α-Klotho co-dependent and independent functions. Curr Opin Nephrol Hypertens. 2018; 28(1):16-25. PMC: 6258326. DOI: 10.1097/MNH.0000000000000467. View

Lisonkova S, Joseph K . Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol. 2013; 209(6):544.e1-544.e12. DOI: 10.1016/j.ajog.2013.08.019. View

10.

Davis G, Mackenzie C, Brown M, S Homer C, Holt J, McHugh L . Predicting transformation from gestational hypertension to preeclampsia in clinical practice: a possible role for 24 hour ambulatory blood pressure monitoring. Hypertens Pregnancy. 2007; 26(1):77-87. DOI: 10.1080/10641950601147952. View

11.

Liu C, Cheng P, Chang S . Maternal complications and perinatal outcomes associated with gestational hypertension and severe preeclampsia in Taiwanese women. J Formos Med Assoc. 2008; 107(2):129-38. DOI: 10.1016/S0929-6646(08)60126-6. View

12.

Andrukhova O, Slavic S, Smorodchenko A, Zeitz U, Shalhoub V, Lanske B . FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med. 2014; 6(6):744-59. PMC: 4203353. DOI: 10.1002/emmm.201303716. View

13.

Loichinger M, Towner D, Thompson K, Ahn H, Bryant-Greenwood G . Systemic and placental α-klotho: Effects of preeclampsia in the last trimester of gestation. Placenta. 2016; 41:53-61. PMC: 5654625. DOI: 10.1016/j.placenta.2016.03.004. View

14.

Amaro-Gahete F, De-la-O A, Jurado-Fasoli L, Ruiz J, Castillo M, Gutierrez A . Role of Exercise on S-Klotho Protein Regulation: A Systematic Review. Curr Aging Sci. 2018; 11(2):100-107. DOI: 10.2174/1874609811666180702101338. View

15.

Uzun Cilingir I, Varol F, Gurkan H, Sutcu H, Atli E, Eker D . Placental and serum levels of human Klotho in severe preeclampsia: A potential sensitive biomarker. Placenta. 2019; 85:49-55. DOI: 10.1016/j.placenta.2019.08.084. View

16.

Mohammadi M, Olsen S, Ibrahimi O . Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 2005; 16(2):107-37. DOI: 10.1016/j.cytogfr.2005.01.008. View

17.

Giannubilo S, Cecati M, Saccucci F, Emanuelli M, Tranquilli A . PP008. Placental klotho gene in preeclampsia. Pregnancy Hypertens. 2015; 3(2):70. DOI: 10.1016/j.preghy.2013.04.036. View

18.

Braithwaite V, Mwangi M, Jones K, Demir A, Prentice A, Prentice A . Antenatal iron supplementation, FGF23, and bone metabolism in Kenyan women and their offspring: secondary analysis of a randomized controlled trial. Am J Clin Nutr. 2021; 113(5):1104-1114. PMC: 8106766. DOI: 10.1093/ajcn/nqaa417. View

19.

. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020; 135(6):e237-e260. DOI: 10.1097/AOG.0000000000003891. View

20.

Lo J, Mission J, Caughey A . Hypertensive disease of pregnancy and maternal mortality. Curr Opin Obstet Gynecol. 2013; 25(2):124-32. DOI: 10.1097/GCO.0b013e32835e0ef5. View